



**PATIENT**

Benji Buck

**SPECIES**

Canine

**BREED**

Poodle Mix

**SEX**

Female Spayed

**AGE**

9 years

**WEIGHT**

28.9lbs

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

**IMAGING PERFORMED BY**

Mark van Campen,  
DVM

**HOSPITAL NAME**

Renfrew Animal  
Hospital

**REFERRING VET**

Dr. van Campen

**INVOICE**

46357

**DATE**

1/8/26

**PRESENTING CLINICAL SIGNS**

History: Grade 4/6 heart murmur. VHS: 11.5 on CXR. Started Pimobendan today. Asses prior to dental. Sedated with Gabapentin and Trazadone.

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and doppler imaging is available. The mitral valve is diffusely thickened with minimal prolapse into the left atrial lumen. There is severe eccentric mitral regurgitation present. The MR velocity is normal. There is severe left atrial enlargement. There is mild left ventricular dilation. Left ventricular systolic function is mildly depressed. Mild right atrial and ventricular dilation (subjective). Mild thickening of the tricuspid valve with trace TR. Normal velocity. The aortic valve appears trileaflet with normal mobility. No significant AI. There is normal systolic flow velocity across the aortic valve. The main pulmonary artery is normal in diameter. The pulmonic valve is normal in appearance. Flow through the RVOT/PV is normal in velocity. Trace PI. No pericardial/pleural effusion or cardiac masses are seen.

**CARDIAC CHART**

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.0	2.0	NM	2.8	35	68	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	NM	1.2	0.8	13.1	3.8	4.3	2.8
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

**INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

Chronic degenerative valve disease causing severe mitral and trace tricuspid regurgitation. The LA is significantly dilated, indicating a high risk for clinical signs going forward. The LV function is mildly depressed, which may be secondary to volume overload. A diet history should be obtained. No additional concurrent issues such as systolic dysfunction are documented.

With this degree of left heart changes, the risk for spontaneous congestive heart failure is elevated and cardiac supportive medications are indicated as below. A weak diuretic (spironolactone) is included given high risk for decompensation in the future even with no reported symptoms for potential survival benefit. Assessment of progression in the future will



## PATIENT

Benji Buck

help predict long term outcome; however, prognosis is guarded at this stage (late B2). Unfortunately there is increased risk for CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future.

## SPECIES

Canine

Close monitoring for development of associated clinical signs (development of a cough, labored breathing, exercise intolerance or worsening collapse episodes) is recommended. **Monitoring of sleeping breathing rates is recommended as the best way to screen for CHF at home.**

## BREED

Poodle Mix

**Elective anesthesia is not advised with severe disease**, as there is high risk for complication. Risk versus benefit must be considered. If necessary, cardiac protective drug choices (opioid/benzodiazepine premedication, propofol or alfaxalone induction, iso or sevoflurane gas) are recommended. Pre-oxygenate for 5-10 minutes prior to induction and recover in O2 cage. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Moderate IV fluid restriction is recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated. Avoid alpha 2 agonists.

## SEX

Female Spayed

## AGE

9 years

Omega fatty acid supplementation and mild salt restriction may also be of some long term benefit.

## WEIGHT

28.9lbs

## PLAN

A screening BP is recommended. Continue Pimobendan 0.3mg/kg PO q12h. Institute ACE-I (benazepril or enalapril) 0.5mg/kg PO q12h. Institute spironolactone 1-2mg/kg PO q12h. Diet history should be obtained.

## INTERPRETED BY


Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

Monitor renal values/BP 1-2 weeks, then every 3-4 months lifelong to ensure tolerance of medications.

A recheck echocardiogram is recommended in 6 months to screen for progression, sooner if clinical signs arise in the interim.

## IMAGING PERFORMED BY

Mark van Campen,  
DVM



## HOSPITAL NAME

Renfrew Animal  
Hospital

## REFERRING VET

Dr. van Campen

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

## INVOICE

46357

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

## DATE

1/8/26

Maggie Machen Lamy, DVM  
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)  
info@sonopath.com